| General Information | |
|---|---|
| ZINC ID | ZINC000049767294 |
| Molecular Weight (Da) | 554 |
| SMILES | O=C(NC1CCCCCC1)c1nn(-c2ccccc2Cl)c(-c2ccc(Br)cc2)c1Cn1cncn1 |
| Molecular Formula | C26Br1Cl1N6O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 144.898 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 35 |
| LogP | 5.762 |
| Activity (Ki) in nM | 2.6915 |
| Polar Surface Area (PSA) | 77.63 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.186 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.31 |
| Ilogp | 4.27 |
| Xlogp3 | 6.51 |
| Wlogp | 6.05 |
| Mlogp | 4.53 |
| Silicos-it log p | 4.56 |
| Consensus log p | 5.18 |
| Esol log s | -7.38 |
| Esol solubility (mg/ml) | 0.0000232 |
| Esol solubility (mol/l) | 4.18E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.94 |
| Ali solubility (mg/ml) | 0.00000641 |
| Ali solubility (mol/l) | 1.16E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.95 |
| Silicos-it solubility (mg/ml) | 0.00000062 |
| Silicos-it solubility (mol/l) | 1.13E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.06 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.75 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.976 |
| Logd | 4.6 |
| Logp | 5.747 |
| F (20%) | 0.002 |
| F (30%) | 0.002 |
| Mdck | - |
| Ppb | 97.76% |
| Vdss | 2.314 |
| Fu | 2.04% |
| Cyp1a2-inh | 0.333 |
| Cyp1a2-sub | 0.108 |
| Cyp2c19-inh | 0.89 |
| Cyp2c19-sub | 0.089 |
| Cl | 4.942 |
| T12 | 0.034 |
| H-ht | 0.364 |
| Dili | 0.987 |
| Roa | 0.912 |
| Fdamdd | 0.512 |
| Skinsen | 0.554 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.654 |
| Bcf | 1.564 |
| Igc50 | 4.896 |
| Lc50 | 6.209 |
| Lc50dm | 4.467 |
| Nr-ar | 0.005 |
| Nr-ar-lbd | 0.007 |
| Nr-ahr | 0.911 |
| Nr-aromatase | 0.992 |
| Nr-er | 0.619 |
| Nr-er-lbd | 0.027 |
| Nr-ppar-gamma | 0.896 |
| Sr-are | 0.883 |
| Sr-atad5 | 0.117 |
| Sr-hse | 0.698 |
| Sr-mmp | 0.88 |
| Sr-p53 | 0.845 |
| Vol | 495.734 |
| Dense | 1.114 |
| Flex | 0.233 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.295 |
| Synth | 2.607 |
| Fsp3 | 0.308 |
| Mce-18 | 62.706 |
| Natural product-likeness | -1.606 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |